Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. more
Time Frame | TRDA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.04% | -3.39% | 0.2% |
1-Month Return | 5.73% | -1.92% | 2.72% |
3-Month Return | 30.3% | -10.54% | 7.31% |
6-Month Return | 21.3% | -4.47% | 10.44% |
1-Year Return | 26.89% | 4.06% | 27.53% |
3-Year Return | 20.2% | 0.94% | 30.88% |
5-Year Return | -22.96% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 25.26M | 129.01M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":19.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 104.00K | 326.00K | 1.12M | 1.90M | 99.88M | [{"date":"2019-12-31","value":0.1,"profit":true},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":1.12,"profit":true},{"date":"2022-12-31","value":1.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (104.00K) | (326.00K) | (1.12M) | (1.90M) | 29.13M | [{"date":"2019-12-31","value":-0.36,"profit":false},{"date":"2020-12-31","value":-1.12,"profit":false},{"date":"2021-12-31","value":-3.83,"profit":false},{"date":"2022-12-31","value":-6.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (7.50%) | 22.58% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-33.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 11.82M | 26.67M | 51.13M | 97.25M | 132.18M | [{"date":"2019-12-31","value":8.95,"profit":true},{"date":"2020-12-31","value":20.18,"profit":true},{"date":"2021-12-31","value":38.68,"profit":true},{"date":"2022-12-31","value":73.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (11.82M) | (26.67M) | (51.13M) | (97.25M) | (3.16M) | [{"date":"2019-12-31","value":-1182400000,"profit":false},{"date":"2020-12-31","value":-2666700000,"profit":false},{"date":"2021-12-31","value":-5112700000,"profit":false},{"date":"2022-12-31","value":-9724800000,"profit":false},{"date":"2023-12-31","value":-316200000,"profit":false}] |
Total Non-Operating Income/Expense | 7.17M | 288.00K | (62.00K) | 5.26M | 27.09M | [{"date":"2019-12-31","value":26.48,"profit":true},{"date":"2020-12-31","value":1.06,"profit":true},{"date":"2021-12-31","value":-0.23,"profit":false},{"date":"2022-12-31","value":19.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (5.10M) | (26.52M) | (51.16M) | (94.62M) | 12.06M | [{"date":"2019-12-31","value":-42.3,"profit":false},{"date":"2020-12-31","value":-220,"profit":false},{"date":"2021-12-31","value":-424.34,"profit":false},{"date":"2022-12-31","value":-784.8,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (451.00K) | (144.00K) | (1.09M) | (7.16M) | 18.74M | [{"date":"2019-12-31","value":-2.41,"profit":false},{"date":"2020-12-31","value":-0.77,"profit":false},{"date":"2021-12-31","value":-5.79,"profit":false},{"date":"2022-12-31","value":-38.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (4.65M) | (26.38M) | (50.07M) | (87.46M) | (6.68M) | [{"date":"2019-12-31","value":-464900000,"profit":false},{"date":"2020-12-31","value":-2637900000,"profit":false},{"date":"2021-12-31","value":-5007200000,"profit":false},{"date":"2022-12-31","value":-8745700000,"profit":false},{"date":"2023-12-31","value":-668500000,"profit":false}] |
Income From Continuous Operations | (5.10M) | (26.52M) | (51.16M) | (94.62M) | (21.77M) | [{"date":"2019-12-31","value":-510000000,"profit":false},{"date":"2020-12-31","value":-2652300000,"profit":false},{"date":"2021-12-31","value":-5115800000,"profit":false},{"date":"2022-12-31","value":-9461600000,"profit":false},{"date":"2023-12-31","value":-2177000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.65M) | (26.38M) | (50.07M) | (87.46M) | (6.68M) | [{"date":"2019-12-31","value":-464900000,"profit":false},{"date":"2020-12-31","value":-2637900000,"profit":false},{"date":"2021-12-31","value":-5007200000,"profit":false},{"date":"2022-12-31","value":-8745700000,"profit":false},{"date":"2023-12-31","value":-668500000,"profit":false}] |
EPS (Diluted) | (5.18) | (12.26) | (18.20) | (3.02) | (0.26) | [{"date":"2019-12-31","value":-518.12,"profit":false},{"date":"2020-12-31","value":-1226.31,"profit":false},{"date":"2021-12-31","value":-1820.19,"profit":false},{"date":"2022-12-31","value":-302,"profit":false},{"date":"2023-12-31","value":-26,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TRDA | |
---|---|
Cash Ratio | 6.36 |
Current Ratio | 6.59 |
Quick Ratio | 6.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TRDA | |
---|---|
ROA (LTM) | 6.95% |
ROE (LTM) | 16.42% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TRDA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TRDA | |
---|---|
Trailing PE | 12.81 |
Forward PE | 3333.33 |
P/S (TTM) | 3.21 |
P/B | 1.63 |
Price/FCF | NM |
EV/R | 1.40 |
EV/Ebitda | 4.93 |
Entrada Therapeutics Inc (TRDA) share price today is $17.732
Yes, Indians can buy shares of Entrada Therapeutics Inc (TRDA) on Vested. To buy Entrada Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRDA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Entrada Therapeutics Inc (TRDA) via the Vested app. You can start investing in Entrada Therapeutics Inc (TRDA) with a minimum investment of $1.
You can invest in shares of Entrada Therapeutics Inc (TRDA) via Vested in three simple steps:
The 52-week high price of Entrada Therapeutics Inc (TRDA) is $21.79. The 52-week low price of Entrada Therapeutics Inc (TRDA) is $11.35.
The price-to-earnings (P/E) ratio of Entrada Therapeutics Inc (TRDA) is 12.8125
The price-to-book (P/B) ratio of Entrada Therapeutics Inc (TRDA) is 1.63
The dividend yield of Entrada Therapeutics Inc (TRDA) is 0.00%
The market capitalization of Entrada Therapeutics Inc (TRDA) is $690.40M
The stock symbol (or ticker) of Entrada Therapeutics Inc is TRDA